GSK 704838

Drug Profile

GSK 704838

Alternative Names: GSK704838

Latest Information Update: 18 Feb 2014

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antiasthmatics
  • Mechanism of Action Cholinergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 18 Feb 2014 Discontinued - Phase-I for Chronic obstructive pulmonary disease in United Kingdom (Inhalation)
  • 29 Feb 2008 GlaxoSmithKline completes a phase I trial in Healthy volunteers in United Kingdom (NCT00539825)
  • 30 Sep 2007 Phase-I clinical trials in Chronic obstructive pulmonary disease in United Kingdom (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top